In our institute, contrast to clinical trial protocols, we have aimed to discontinue trastuzumab treatment if a patient with metastatic HER2 positive breast cancer has achieved prolonged radiological response and have seen that these patients can experience long trastuzumab-free treatment periods33. Here, ERBB2 is linked to breast cancer.